Research programme: miniaturised sustained release therapeutics - pSivida

Drug Profile

Research programme: miniaturised sustained release therapeutics - pSivida

Alternative Names: TBD; Tethadur™ - pSivida

Latest Information Update: 09 Feb 2015

Price : $50

At a glance

  • Originator pSivida
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Glaucoma; Retinitis pigmentosa

Most Recent Events

  • 05 Feb 2015 Preclinical development in dry Age-related macular degeneration is ongoing in USA
  • 09 Sep 2014 pSivida intends to advance the preclinical develoment of its proprietary Tethadur™ technology for sustained delivery of peptides and proteins (including antibodies)
  • 13 May 2014 Research programme: eye disorder therapeutics - pSivida is available for licensing as of 13 May 2014. www.pSivida.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top